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ABSTRACT In this study, we describe an in silico method to design peptides that can be made of non-natural amino acids and
elicit speciﬁc membrane-interacting properties. The originality of the method holds in the capacities developed to design
peptides from any non-natural amino acids as easily as from natural ones, and to test the structure stability by an angular
dynamics rather than the currently-used molecular dynamics. The goal of this study was to design a non-natural tilted peptide.
Tilted peptides are short protein fragments able to destabilize lipid membranes and characterized by an asymmetric distribution
of hydrophobic residues along their helix structure axis. The method is based on the random generation of peptides and their
selection on three main criteria: mean hydrophobicity and the presence of at least one polar residue; tilted insertion at the level
of the acyl chains of lipids of a membrane; and conformational stability in that hydrophobic phase. From 10,000,000 randomly-
generated peptides, four met all the criteria. One was synthesized and tested for its lipid-destabilizing properties. Biophysical
assays showed that the ‘‘de novo’’ peptide made of non-natural amino acids is helical either in solution or into lipids as tested by
Fourier transform infrared spectroscopy and is able to induce liposome fusion. These results are in agreement with the cal-
culations and validate the theoretical approach.
INTRODUCTION
Designed peptides have been used in the last decade to
improve our understanding in the structure/function relation-
ship of proteins. This design approach notably helps us to
understand the structural determinants of folds, such as those
of b-sheets (1). The current methods use statistical analysis
of protein-structure databank and empirical information
(2–4). Rotamer analysis can also be performed to check the
compatibility of side-chain packing.
Modiﬁed or non-natural amino acids are notably used to
study the folding, the conformational stability, and the ﬂex-
ibility of peptides and proteins (5–9). Non-natural amino acids
can be more resistant to protease degradation and have a
decreased immunogenicity (10).
Model peptides can also be used to explore features re-
sponsible for the association of hydrophobic peptides derived
from a water-soluble coiled-coil structure in membrane (11).
In the same way, designed pore-forming peptides are useful
models to enable us to better understand the insertion of
proteins in biomembranes (12).
Peptides with antitumoral or antibacterial activity were also
designed to investigate structural parameters of their lytic
activity and selectivity, notably their membrane speciﬁcity
(13,14).
In these cases, design of peptides with improved activity
and/or selectivity might be helpful for biological and thera-
peutic uses.
In this study, we describe an original in silico method to
design peptides with desired features, notably with speciﬁc
membrane-interacting properties. We applied this method to
the design of tilted peptides. The latter are short protein
fragments able to destabilize membranes (15). When tilted
peptides are modeled as a-helices, an asymmetric distribu-
tion of hydrophobicity is responsible for an oblique orienta-
tion at a hydrophobic/hydrophilic interface, such as amembrane
(16). Tilted peptides were notably found in viral fusion
proteins where they are involved in the ﬁrst steps of fusion
between the host cell and the virus membrane (17). They
were also detected in proteins involved in lipid metabolism,
in signal sequences, in toxins, etc. (18). Many among the in
silico detected peptides were experimentally conﬁrmed. Most
were shown to induce liposome fusion in vitro when taken
as isolated fragments (19–24). Furthermore, when the pep-
tides were mutated to modify the hydrophobicity distribution,
fusogenic properties were signiﬁcantly decreased. When the
same mutations were introduced in the protein, its activity was
modiﬁed (23,25). Neutron diffraction experiments showed that
one structural conformer of the tilted peptide from the gp32
fusion protein of simian immunodeﬁciency virus (SIV) is
oriented at an angle of 55 in a model membrane (26). In the
same way, the NMR structures of the HA2 fusion peptide from
the Inﬂuenza virus were shown to be obliquely oriented in
model membranes at the active pH (27).
Comparison of tilted peptides demonstrated no sequence
homology (28); the only characters they shared were their
mean hydrophobicity (following the Eisenberg consensus
scale (29)) between 0.2 and 0.9, an asymmetric hydropho-
bicity gradient when helical and an insertion angle of this
helix into lipids between 30 and 60.
In this article, we report a modeling approach for the
rational design of hydrophobic peptides entirely made from
non-natural amino acids. The goal was to make a tilted
peptide, i.e., a short 12-residue fragment with a mean
hydrophobicity between 0.6 and 0.7 and a lipid-insertion
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angle close to 45 due to the asymmetric distribution of hy-
drophobic residues. One predicted sequence has been syn-
thesized and experimentally tested for its lipid-destabilizing
capacities.
MATERIALS AND METHODS
Molecular modeling materials
Egg phosphatidylcholine (PC), phosphatidylinositol (PI), phosphatidylser-
ine (PS), cholesterol (CHOL), and sphingomyelin (SM) were purchased
from Sigma (St. Louis, MO). Egg phosphatidylethanolamine (PE) is from
Lipid Products (Redhill, Surrey). Octadecyl rhodamine chloride (R18) is
from Molecular Probes (Eugene, OR).
The peptides were obtained from Neosystem (Strasbourg, France). They
were 85% pure.
Molecular modeling methods
Orientation at the lipid-water interface (TAMMO orientation)
Each molecule structure is oriented with respect to the spatial distribution of
its hydrophobicity. The line joining the hydrophilic and hydrophobic centers
is set to be perpendicular to the hydrophobicity interface (30). The hydro-
phobic center (C~phi) is deﬁned by the equation
C~phi ¼
+Ephitri r~i
+Ephitri
; (1)
in which the r~i values are the coordinates of the i
th atom, and Etr(i) its transfer
energy per unit of accessible surface. The hydrophobic center located in the
hydrocarbon domain (C~pho) is deﬁned by the same equation, except that the
negative transfer energies are taken into account. The interface position (I~) is
deﬁned by
+Ephotr
jI~ C~phoj
¼ +E
phi
tr
jI~ C~phij
: (2)
Membrane insertion
We inserted peptides into an implicit bilayer integral membrane protein and
lipid association (IMPALA) developed by Ducarme et al. (31). It simulates
the insertion of any molecule (protein, peptide, or drug) into a bilayer by
adding energy restraint functions to the usual energy description of mole-
cules (32,33).
The lipid bilayer is deﬁned by C(z), which represents an empirical func-
tion describing membrane properties. This function is constant in the mem-
brane plane (x- and y-axes) but varies along the bilayer thickness (z-axis) and
more speciﬁcally, at the lipid/water interface corresponding to the transition
between lipid acyl chains (no water¼ hydrophobic core) and the hydrophilic
aqueous environment,
CðzÞ ¼ 1 1
11 eaðzz0Þ
; (3)
where a is a constant equal to 1.99, z0 corresponds to the middle of polar
heads, and z is the position in the membrane. This function can be different
for each layer according to the asymmetric composition of the membrane.
Two restraints simulate the membrane—one the bilayer hydrophobicity
(Epho), and the other, the lipid perturbation (Elip).
The hydrophobicity of the membrane is simulated by Epho,
Epho ¼ +
N
i¼1
SðiÞEtrðiÞCðziÞ; (4)
where N is the total number of atoms, S(i) the accessible surface to solvent
of the i atom, Etr(i) its transfer energy per unit of accessible surface area, and
C(z) the zi position of atom i.
The perturbation of the bilayer by insertion of the molecule is simulated
by the lipid perturbation restraint (Elip),
Elip ¼ alip +
N
i¼1
SðiÞð1 CðziÞÞ; (5)
where alip is an empirical factor ﬁxed at 0.018 kcal.mol
1 A˚2.
The environment energy (Eenv) applied on the peptide that inserts into the
membrane becomes equal to
Eenv ¼ Epho1Elip: (6)
Systematic analysis. A systematic procedure is performed to insert and
orient the peptide into the membrane. During this process, the peptide
systematically crosses the force ﬁeld of the membrane from 40 to 140 A˚
with respect to the membrane center by steps of 1 A˚. For each position along
the z axis, 2000 random orientations are tested. Among these 2,000
positions, the minimal energy position is selected. At the end of the
systematic analysis, the procedure selects the position and the orientation of
minimum energy among all selected minima.
Angular dynamics optimization
To analyze structural variations of the peptide inserted in the membrane, we
have used the angular dynamics procedure previously deﬁned to simulate
the protein folding (34).
In the simulations, the total energy (Etot) is the sum of the intramolecular
energy of the peptide (Eintra) and of the energy due to the membrane envi-
ronment (Eenv). Etot is distributed at each step of the calculation on the peptide
torsion k-axis as E(k). This total energy is equal to
Etot ¼ Eintra1Eenv ¼ +
k
EðkÞ: (7)
The intramolecular energy Eintra is composed by Evdw, the Van der Waals
energy that represents the interaction of the electronic cloud of the atoms,
and is described by the Levitt’s equation (35)
E
ij
vdw ¼ +
N1
i¼1
+
N
j¼i11
A=d
12
ij  B=d6ij
h i
=
n
A=d
12
ij
 
11 0:1 d2ij
 
=h1 1
h io
; (8)
where A and B are speciﬁc parameters for each atom pair and dij is the dis-
tance between the two nonbonded atoms i and j. The second bracket termmakes
the atoms soft and the parameter h is taken as 1,000 kcal/mol.
Eelec, the electrostatic energy is given by the classical Coulomb’s law that
takes into account the point-charge of the atoms (qi and qj), the dielectric
constant, and the distance (dij) between atoms i and j,
E
ij
elec ¼ l +
N1
i¼1
+
N
j¼i11
qiqj
dijÆeijðzÞæ
 
; (9)
where l is the electronic density unit conversion factor and Æeij(z)æ is the
dielectric constant, a sigmoid function of the distance between atoms in
interaction.
Epho_in is the intramolecular hydrophobic energy,
E
ij
pho in ¼ +
N1
i¼1
+
N
j¼i1 1
dij jEitr fijj1 jEjtr fjij
 
exp
ri1 rj  rij
2rsol
 
;
(10)
where Etr is the free energy transfer of the atoms i and j; fij and fji are the
factors of atomic recovery by atom i on atom j, and conversely; ri and rj the
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Van der Waals radius of the atoms i and j; rsol the radius of water molecule;
dij the distance between atoms i and j; dij ¼ 1 if atoms are from the same
type (hydrophobic or hydrophilic), and dij ¼ 11 if atoms are from opposite
type (hydrophobic and hydrophilic).
The energy of each axis ((SE(k)) is supplemented by its own torsion
energy (E(k)tor),
EðkÞtor ¼
UðkÞ
2
f11 cos½b3 xðkÞg; (11)
where U(k) corresponds to the energy barrier in the eclipsed conformation
during the rotation of the k angle, b is the periodicity of the function, and j(k)
is the value of the torsion k angle. U(k) is equal to 48.95 kcal/mol for the
C-C bond and 31.38 kcal/mol for the C-O bond.
The total energy associated with each torsion axis (E(k)) is therefore
represented by the sum of 1), the torsion energy of the k axis (E(k)tor); 2), the
intramolecular interaction energies between atoms i and j, divided by the
number of axes between these atoms; and 3), the energy in the membrane
for the atoms i and j divided by the number of atoms of the system minus
1 (N1) and by the number of axes between atoms i and j,
EðkÞ ¼ EðkÞtor|ﬄﬄ{zﬄﬄ}
A
1 +
w
i¼1
+
N
j¼w11
f E
ij
vdw1E
ij
elec1E
ij
pho in
 
|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
B
1 +
w
i¼1
+
N
j¼w11
f
Eenv
N  1|ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
C
; (12)
with f ¼ 1/number of axes between i and j.
The energy E(k) allows us to calculate an angular dynamics that gives rise
to an acceleration of torsion axes.
During the dynamics, the length of atomic bonds and the value of valence
angles are kept constant; only the torsion angles are modiﬁed. The angular
acceleration of each torsion axis is determined following Newton’s equation,
dEðkÞ
dt
¼ mrðkÞ3aðkÞ; (13)
where a(k) is the angular acceleration of the angle k and mr(k) is the reduced
mass calculated from the mass of the atoms on both sides of the torsion
axis k,
mrðkÞ ¼
+
w
i¼1
mi3 +
N
j¼w11
mj
+
N
i¼1
mN
; (14)
where mi, mj are the mass of the atoms before and after the torsion axis
except the atoms deﬁning the axis, and mN is the total mass of the molecule.
Knowing the angular acceleration of the torsion axes, the t11 position of
each torsion axis (j(k)theo) can be determined following the equation derived
by Verlet (36),
xðkÞtheot11 ¼ 2xðkÞt  xðkÞt11
Dt
2
mrðkÞ
½EðkÞt1  EðkÞt
½xðkÞt  xðkÞt1
	 

;
(15)
where j(k) is the value of the torsion angle k.
At each step, E(k)t is the energy associated to an angle k at t time and is
given by Eq. 12.
During the angular dynamics, the rotation velocity vr(k), expressed as
a function of Dt is calculated according to
vrðkÞ ¼ jðkÞt  jðkÞt11: (16)
In Eqs. 15 and 16, Dt ¼ 1.
The rotation velocity vr(k) used in our calculations is limited to 0.075/
step. It is an arbitrary empirical value that seems to be sufﬁcient for a rapid
molecule movement and slow enough to prevent molecule burst. During all
the calculation, the movement quantity (Q) was kept constant,
Qint ¼ +
k
mrðkÞ3 0:075; (17)
with Qint representing the initial quantity of movement.
As the velocity changes at time t11 the theoretical movement quantity
becomes Qt11,
Qt11 ¼ +
k
mrðkÞ3 vrðkÞ; (18)
where the rotational velocity (v(k)) becomes vr*(k) to maintain the Qint
constant. This is achieved via a correcting factor f (with f ¼ Qint/Qt11),
v

r ðkÞ ¼ vrðkÞ3 f : (19)
This velocity variation of k is used to give the new value of j(k) at time t11,
jðkÞ0t11 ¼ jðkÞt1 vr ðkÞt11: (20)
A small random component (md(k)) is added to j(k). The ﬁnal value of
j(k)t11 is
jðkÞt11 ¼ jðkÞ0t111mdðkÞ: (21)
This random parameter md(k) is introduced to mimic the thermal motion of
the system and to enable us to bypass energy barriers during the simulations.
It represents one-tenth to one-third of the initial rotation velocity.
A t ¼ 0, the position and orientation of the peptide in the membrane are
those determined from the IMPALA systematic analysis (see above). From
there, an angular dynamics is performed on the peptide taking into account
the mean force ﬁeld of the membrane. Random rotations of 1 max and ran-
dom translations of 0.1 A˚ max of the peptide are allowed.
Experimental materials
Calculations are performed on an Intel Pentium 4, 3.80-GHz CPU, with 4.00
Gb of RAM.
Pex2dstats ﬁles (37) are generated during the simulations and used for the
analysis of each peptide. The mean gain ratio of angular versus molecular
dynamics was calibrated to 1/100–1/1000 the number of calculation steps
when only side chains or side chains plus backbone movements were
calculated.
Experimental methods
Liposome preparation
Large unilamellar vesicles (LUV) were prepared by the extrusion technique
(38) using an extruder (Lipex Biomembranes, Vancouver, Canada). In brief,
dry lipid ﬁlms which are mixtures in weight of 30% phosphatidylcholine
(PC), 30% phosphatidylethanolamine (PE), 2.5% phosphatidylinositol (PI),
10% phosphatidylserine (PS), 5% sphingomyelin (SM), and 22.5% cho-
lesterol were hydrated for 1 h at 37C. The resulting suspension was sub-
mitted to ﬁve successive cycles of freezing and thawing and thereafter
extruded 10 times through two stacked polycarbonate ﬁlters (pore size
0.08 mm) under a nitrogen pressure of 20 bars.
The ﬁnal concentration of liposomes was determined by phosphorus
analysis (39).
Lipid-mixing experiments
Mixing of liposome membranes was followed by measuring the ﬂuores-
cence increase of R18, a lipid soluble probe, occurring after the fusion of
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labeled and unlabeled liposomes, as described (40). Labeled liposomes were
obtained by incorporating R18 in the dry lipid ﬁlm at a concentration 6.3%
of the total lipid weight. Labeled and unlabeled liposomes were mixed at a
weight ratio 1:4 and a ﬁnal concentration of 50 mM in 10 mM Tris, 150 mM
NaCl, 0.01% EDTA, and 1 mM NaN3, pH 8. Fluorescence was recorded at
room temperature (lexc, 560 nm; lem, 590 nm) on an LS-50B Perkin-Elmer
ﬂuorimeter (Boston, MA).
Leakage of liposome vesicle contents
The 8-hydroxypyrene-1,3,6-trisulfonic acid (HPTS)/p-xylylenebis[pyridi-
nium] bromide (DPX) assay of Ellens et al. (41) was used to monitor vesicle
leakage. The assay is based on the quenching of HPTS by DPX. HPTS and
DPX are both encapsulated in the aqueous phase of the same liposomes.
Leakage of vesicles was followed by measuring the dequenching of HPTS
released into the medium. Fluorescence was recorded at room temperature
(lexc, 360 nm; lem, 520 nm) on a LS-50B Perkin-Elmer ﬂuorimeter.
Core-mixing experiments
The mixing of liposome contents was monitored using the core-mixing assay
of Kendall and McDonald (42). Liposomes (LUV) were prepared as de-
scribed above in 10 mM Tris-HCl buffer, 150 mM NaCl, and 1 mM NaN3,
pH 8.0 and containing calcein at 0.8 mM and CoCl2 at 1.0 mM or EDTA at
20 mM. Untrapped solutes were removed by one elution on a Sephadex
G-75 column (Sigma-Aldrich) with 10 mM Tris-HCl, 150 mM NaCl, and
1 mM NaN3 buffer, pH 8.0. In a standard experiment, calcein, Co
21- and
EDTA-containing vesicles were mixed at 1:1 molar ratio in a 10 mM Tris-
HCl buffer, pH 8.0 (150 mM NaCl, 1 mM NaN3). When peptides were
added, the calcein ﬂuorescence was monitored at room temperature (lexc,
490 nm; lem, 520 nm) as a function of time on a LS-50B Perkin-Elmer
ﬂuorimeter. Co21 (0.4 mM in chelation with citrate at 1:1 mol/mol) was
present in the medium to avoid ﬂuorescence due to leakage of vesicle
contents. The maximum ﬂuorescence was determined in presence of Triton
X-100, 0.5% (10 mM EDTA).
Infrared spectroscopy Fourier-transform infrared
(FTIR) measurements
Attenuated total reﬂection (ATR) infrared spectroscopy was used to deter-
mine the secondary structure of the peptides alone and bound to lipids.
Spectra were recorded at room temperature on a Bruker Equinox 55
(Bruker AXS, Karlsruhe, Germany) equipped with a liquid nitrogen-cooled
Mercury-Cadmium-Telluride detector at a resolution of 2 cm1, by aver-
aging 512 scans. Free peptide samples (20 mg peptide) dissolved in TFE
and the lipid-bound peptides (see preparation below) were spread out on
a germanium ATR plate (50 3 20 3 2 mm—Aldrich Chimica, Milan,
Italy—with an aperture of 45 yielding 25 internal reﬂections) and slowly
dried under a stream of N2. Reference spectra of a Germanium plate were
automatically recorded after purge for 15 min with dry air and subtracted to
the recently run sample spectra. The plate was sealed in an universal sample
holder and hydrated by ﬂushing the holder with N2 saturated with D2O for
3 h at room temperature.
Peptide/lipid sample preparation
A dried mixed ﬁlm made of 20 mg peptide and 100 mg lipids (PC/PE
2:1 w/w) was hydrated with 100 ml of a 10 mM Tris, 150 mM NaCl, pH 8
buffer.
Phospholipid concentration was determined as mentioned above.
Secondary structure determination
Vibrational bands, especially the amide I band (1600–1700 cm1), are
sensitive to the secondary structures of proteins. The C¼O vibration is
representative of 80% of the amide I band. This band accounts for all
secondary structures which have different vibration values. The combination
of resolution-enhancement methods with curve-ﬁtting procedures allow us
to assign quantitatively different secondary structures such as a-helix,
b-sheets, and unordered structures. Each band was assigned according to the
frequency of its maximum. The areas of all bands assigned to a given
secondary structure were then summed and divided by the sum of all areas.
This gives the relative ratio of each secondary structure. The bands are as-
signed as follows: a-helix, 1662–1645 cm1; b-sheets, 1689–1682 cm1
and 1637–1613 cm1; random, 1644.5–1637 cm1; and b-turns, 1682–
1662 cm1. It should be noted that the proteins spread on the plate are
deuterated to avoid an overlap of a-helix and random-coil structures, as
previously described (43,44).
RESULTS
Single-letter and three-letter codes were assigned to the 14
non-natural amino acids that we used throughout the study
(Table 1). These amino acids, which are commercially avail-
able, are called modiﬁed or non-natural because they have
the same backbone as the 20 residues found in eukaryotic
proteins but have different side chains. None of the selected
amino acids contains a halogen or a potentially toxic atom.
The structures of the 14 selected amino acids were modeled
using HyperChem 5.0 (Hypercube, Gainesville, FL), starting
from the backbone of alanine and optimized by the Polak-
Ribiere algorithm using an AMBER force ﬁeld with a gra-
dient d inferior to 0.1 kcal/(A˚ mol).
The peptide length is ﬁxed to 12 residues. All positions
can be taken by any of the 14 non-natural residues, allowing
1412 possible sequences. Due to time constraints, we reduced
the number of sequences to 10,000,000, randomly generated.
Three independent runs of 10,000,000 peptides have been
performed. The results from a single run were selected for
presentation in this article; the two others gave similar results.
Calculation of non-natural amino
acid hydrophobicity
One parameter of selection is the mean peptide hydropho-
bicity. This value is obtained from individual residue hy-
drophobicity, which is unknown for the non-natural residues.
For current amino acids, we use the hydrophobicity scale
of Eisenberg (29). For non-natural amino acids, we de-
veloped a method for estimating an Eisenberg-like hydro-
phobicity value. Hydrophobicity values are usually obtained
from experimental measurements of the transfer energy (Etr)
of molecules from water to an organic phase such as octanol.
Molecular transfer energy can also be calculated from atomic
Etr (Table 1) and the solvent-accessible surface of atoms in
the molecule three-dimensional structures as previously de-
scribed (45). Both Eisenberg’s amino-acid hydrophobicity
values and Brasseur’s calculated Etr values are linearly
correlated with a regression coefﬁcient of 0.75 (Fig. 1). A
75% correlation was here estimated as sufﬁcient since hy-
drophobicity was used as a ﬁlter for selection. Hence from
the calculated three-dimensional structures and the atomic
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Etr scales, the Etr of non-natural amino acids were calculated.
The Eisenberg hydrophobicity values were then extrapolated
using the linear correlation (Fig. 1). Table 1 provides all
Brasseur-calculated Etr and Eisenberg’s consensus hydro-
phobicity values for the 20 natural amino acids and for the 14
non-natural amino acids. Hydrophobicity values of non-
natural amino acids are often a bit lower or higher than those
of natural amino acids. Amino acids of similar structures, such
as (cyclo)hexalanine and (cyclo)hexetamine, or phenyletha-
nine and methylphenylalanine, have very close values. For
residues with increasing numbers of carbons in the lateral
chain, i.e., ethanine, norvaline, allylglycine, terleucine, and
norleucine, the increase in hydrophobicity values goes with
the increase in the number of carbons, as expected for organic
compounds (46). Two non-natural amino acids have a negative
hydrophobicity: orthinine and citrulline; both are charged.
Their hydrophobicity values are close to those of charged and
polar natural amino acids, aspartic acid, asparagine, glutamic
acid, and glutamine.
Peptide selection
The peptide selection process is based on several steps
corresponding to speciﬁc criteria (Fig. 2). The ﬁrst criterion
is the mean hydrophobicity of the peptide. The value is cal-
culated using the scale described above (Table 1). Sequences
are kept when the mean peptide hydrophobicity is between
0.6 and 0.7 kcal/residue. This range was previously shown to
correspond to tilted peptides interacting with lipids (28).
Sequences fulﬁlling this criterion were then three-dimen-
sionally constructed as an a-helix. The distribution of hy-
drophobicity with respect to the helix axis was calculated
by taking into account the geographic centers of hydrophobic
and hydrophilic atoms. The angle between the helix axis and
the molecule hydrophobicity interface of each helix structure
was calculated; only those with angles between 30 and 60
were selected.
In the third step, a systematic IMPALA screening inves-
tigated the helical peptide insertion into a membrane. The
optimal orientation of each helix in membrane was calculated
and peptides presenting an orientation between 35 and 55
were kept. At that step a complementary criterion was in-
troduced, which is that the position of the helix mass center
TABLE 1 Characteristics of the 20 classical amino acids and
the modiﬁed amino acids used in this study
One-letter
symbols
Three-letter
symbols
Atomic or
molecule Etr
(Kcal/mol) ÆHæ
Atoms
Csp2 1.50
Csp3 2.44
H (q¼0) 0.54
H (q/0) 1.03
O 2.83
S 2.75
N 3.04
Natural AA
Glycine G Gly 7.93 0.48
Alanine A Ala 5.52 0.62
Valine V Val 1.99 1.10
Leucine L Leu 1.02 1.10
Methionine M Met 0.25 0.64
Isoleucine I Ile 0.91 1.40
Serine S Ser 11.33 0.18
Threonine T Thr 8.40 0.05
Cysteine C Cys 2.48 0.29
Proline P Pro 1.96 0.12
Asparagine N Asn 14.48 0.78
Glutamine Q Glu 15.68 0.85
Aspartic acid D Asp 14.70 0.90
Glutamic acid E Glu 15.15 0.74
Lysine K Lys 9.38 1.50
Arginine R Arg 17.31 2.50
Histidine H His 11.28 0.40
Phenylalanine F Phe 1.36 1.20
Tyrosine Y Tyr 5.97 0.26
Tryptophan W Trp 1.06 0.81
Non-natural AA
Ethanine 2 Eth 2.60 0.67
Norvaline 3 Nov 1.35 0.85
Norleucine 4 Nol 1.68 1.28
Teurleucine 5 Ter 0.75 1.15
Allylglycine 6 Aly 0.76 0.93
(Cyclo)hexalanine 7 Cha 3.94 1.60
(Cyclo)hexethanine 8 Che 5.16 1.78
Phenylethaline 9 Fet 3.94 1.60
Naphtylalanine B Nap 5.33 1.80
Methylphenylalanine J Mfa 4.11 1.63
Ornithine O Orn 8.59 0.18
Citrulline U Cit 14.10 0.97
Parapyridine X Pap 3.13 0.60
Metapyridine Z Mep 2.38 0.70
Calculated Etr of atoms and of natural amino acids are from Brasseur (45).
The value ÆHæ is the Eisenberg’s mean hydrophobicity of the 20 classical
amino acids derived from Eisenberg et al. (29). The non-natural amino acid
Etr are calculated from the atomic transfer energy and the solvent-accessible
atoms of the HyperChem energy-minimized structures using the Shrake and
Rupley’s algorithm (51).
FIGURE 1 Linear correlation between Eisenberg’s mean hydrophobicity
values of natural amino acids and Brasseur’s calculated Etr of those mole-
cules (open circles). The linear regression coefﬁcient (R2) is indicated; amino
acids are named by their one-letter code. The calculated Etr values of the 14
non-natural amino acids are also plotted (solid squares).
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had to be between 8 and 13 A˚ with respect to the bilayer
center, i.e., near the phospholipid (PL) acyl-chain/headgroup
interface. This restraint was set to choose peptides able to
disturb the PL acyl-chain organization, the ﬁrst step thought
to induce fusion processes (16). The peptides matching the
different criteria were then optimized at the interface by an
angular dynamics, to analyze their conformational stability.
The whole strategy is illustrated in Fig. 2.
From 10,000,000 sequences tested, a quantity of 9,109,270
were rejected by taking into account the mean sequence
hydrophobicity value. Among the remaining number, 822,337
were rejected by taking into account the peptide interface
orientation, and another 67,196 were rejected after the
IMPALA screening, taking into account the angle and the
depth of insertion. At that step, 1197 sequences were re-
tained. To further decrease the number of candidates, one
criterion was added: the peptide had to include one hydro-
philic residue, i.e., citrulline or ornithine. Only 12 peptides
ﬁtted that last criterion. The angular dynamics demonstrated
that four of them were conformationally stable. They cor-
respond to sequences number 48,482; 51,208; 88,682; and
97,848 (Table 2).
The energy minima proﬁles of peptide 97,484 insertion in
the model membrane IMPALA (Fig. 3) demonstrates that
both the pre- and post-angular dynamics structures maxi-
mally insert in a similar way—with their center of mass
between 5 and 13 A˚ from the membrane center (i.e., at the
level of phospholipid headgroup/acyl-chain interface)—and
have a low energy barrier to cross the membrane. This
suggests that the latter structures might have access to a wide
range of membrane levels. If the angular dynamics has had
little consequence on the 97,484 backbone structure sup-
porting our conclusion of helical stability, it modiﬁed the
side-chain orientation and the ﬁnal structure was even more
penalized in water (IMPALA energy values at z over620 A˚)
than the pre-optimized structure. This is illustrated in Fig. 3.
It is also seen while comparing the best conﬁgurations in
membrane for the pre- and post-angular dynamics structures
(Fig. 5 as compared to Fig. 6 f) and also accounts for the
increase of the IMPALA energy when the peptide is sliding
toward the membrane surface after 8000 steps of dynamics
(Fig. 6, a and c). After angular dynamics, side chains of
naphtylalanine and phenylethaline are bent toward the phos-
pholipid polar head interface and the citrulline polar side
chain is partly protruding out of the membrane (Fig. 6, e and f).
Those results suggest that the peptide 97,848 is stable in
the membrane, and can move from the lipid polar head to the
acyl-chain domain in that membrane. This mode of insertion
generates conditions where lipid perturbation may occur and
be responsible for a membrane fusion process. Peptide 97,848
was synthesized and experimentally tested for fusogenic
activity and conformational analysis.
Biophysical assays
Lipid fusion (lipid and core mixing) and leakage assays were
carried out. The SIV fusogenic peptide was used as a positive
FIGURE 2 Schematic representation of the different selection steps in the
de novo generation of tilted peptides.
TABLE 2 Non-natural peptides ﬁtting the criteria
indicated below
Peptide
number Sequence
Insertion
angle ()
Mean
hydrophobicity
22,319 U 5 U 9 4 O O 4 B 2 6 4 55 0.64
31,272 U B J 9 U 7 O U O J J 3 53 0.62
33,687 O O 2 Z 4 Z 3 O 6 5 9 X 26 0.66
48,482 O J 6 9 O 3 U 2 8 9 9 U 48 0.70
50,249 U 9 U 8 X 3 O 8 4 8 U 7 55 0.682
51,208 O U 7 8 Z X O 9 3 9 J U 35 0.67
52,230 O 3 8 O O B O 2 2 4 4 Z 52 0.69
56,571 U Z 6 J 8 5 X 7 U O X X 48 0.62
88,682 O 7 8 O 7 O 9 6 2 U Z 2 50 0.67
97,848 U 9 6 B O 9 O 6 X U 7 4 48 0.67
98,807 U O 8 7 6 O U 7 X J Z 9 53 0.68
99,721 U O 5 7 O 5 U 2 7 J 7 4 55 0.70
Mean hydrophobicity between 0.6 and 0.7, insertion angle between 35 and
55 and mass center located between 8 and 13 A˚ (absolute value) from the
bilayer center in the IMPALA membrane, containing one ornithine or cit-
rulline. The bold peptides are conformationally stable during angular dynamics.
The boxed peptide was used in the experimental part of the study.
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control, since its lipid-destabilizing properties are well known
(20). The induction of vesicular lipid mixing by the different
peptides is tested with PC/PE/SM/PI/PS/Chol LUVs. The
R18-labeled and R18-free liposomes were mixed and the
time-course increase of ﬂuorescence intensity due to the de-
quenching of the probe was measured to follow-up lipid fusion.
Fig. 4 clearly shows that the peptide 97,848 induces lipid
mixing. The process is dose-dependent. The fusogenic activity
of the peptide is further assessed by core mixing experiments
(Table 3). Leakage assays conﬁrmed the lipid-destabilizing
properties of the peptide, as shown in Table 3. The process was
also dependent on the peptide concentration. In three inde-
pendent experiments, the 97,848 peptide appeared slightly but
constantly more potent than the SIV peptide.
The conformation of the peptide alone and in the presence
of lipids was analyzed by attenuated total reﬂection FTIR
spectroscopy (Table 4). The peptide is mainly helical in both
conditions, in agreement with our calculations. It should be
noted that the purity of the peptide is 85%.
DISCUSSION
Automatic design of peptides is little described in the literature.
Some computer programs, such as LUDI,were set to design
protein ligands, from organic compounds to peptidomimetics
(3). It was shown on inhibitors of HIV-1 protease that this
algorithm essentially helps in the initial steps of the design
procedure (47). Other procedures, such as DESIGNER, use
a structure template, a rotamer library, and an empirical force
ﬁeld; this was notably applied to MHC class I binding peptides
(2). Very recently, Decaffmeyer et al. (48) developed an in
silico approach, called Pep Design, to design complementary
peptides. The assay was used to design a partner to the
C-terminal fusion domain of the Ab peptide involved in the
Alzheimer’s disease. The peptide was made from natural amino
acids. The leading idea was derived from the observation that
the lipid-binding domain (and more speciﬁcally the C-terminal
helix) of apolipoprotein E (apoE) is able to decrease the desta-
bilizing properties of the Ab peptide (49,50). The ‘‘de novo’’
peptide, derived from the apoE C-terminal helix is able to in-
teract with the C-terminal fusogenic domain of Ab peptide and
to decrease its lipid-destabilizing properties with a higher efﬁ-
ciency than the apoE wild-type peptide.
FIGURE 3 Best position of peptide 97,848 in the IMPALA membrane
before the angular dynamics. Midplane, bilayer center (z ¼ 0); ﬁrst upper
(beneath) plane; lipid acyl chain/polar headgroups interface at 13.5 A˚ from the
center; and second upper (beneath) plane, lipid/water interface (z ¼ 18 A˚).
FIGURE 4 Time course of lipid mixing of liposomes (LUV) induced by
peptide 97,848. The peptide is added at different concentrations (from 30
mM to 600 mM corresponding to peptide to lipid molar ratio from 1:50 to
2:5) to a mixture (1:4 w/w ratio) of R18-labeled and unlabeled LUVs.
Increase of the R18 relative ﬂuorescence due to probe dilution is followed at
room temperature. The SIV tilted peptide at 150 mM is used as positive
control, the addition of TFE (1.6% ﬁnal concentration) as negative control.
TFE (blank),d; and SIV peptide at 150 mM (positive control),). Addition
of peptide 97,848 at 30 mM (P/L molar ratio, 1:50), s; 60 mM (P/L ratio
1:25),:; 150 mM (P/L ratio 1:10), 3; and 300 mM (P/L ratio 1:5), D.
FIGURE 5 Proﬁle of the minimal IMPALA energy values (in kcal/mol)
versus the mass center position (A˚) of the 97,848 peptide after a systematic
screening of peptide membrane traverse. Peptide 97,848 before the an-
gular dynamics (solid line); and peptide 97,848 after the angular dynamics
(dotted line).
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In this study, we aimed to design peptides made of non-
natural amino acids and eliciting peculiar lipid-interacting
properties mimicking those of lipid-destabilizing tilted
peptides. The in silico selection was based on several criteria
common to tilted peptides (16,28). Tilted peptides are able to
interact with and insert obliquely within a lipid bilayer. This
behavior is notably linked to their mean hydrophobicity
value (the most efﬁcient peptides being between 0.6 and
0.7 kcal/residue according to the hydrophobicity scale of
Eisenberg). Tilted peptides also present an asymmetric
distribution of hydrophobic residues when helical.
A de novo peptide (12 residues long) exclusively made of
non-natural amino acids was developed. Fourteen commer-
cially available non-natural amino acids were selected. They
have a normal backbone conﬁguration but modiﬁed lateral
chains such as aliphatic chains with variable number of car-
bon atoms, double aromatic rings, etc.
Ten million sequences were randomly generated. Taking
into account the mean peptide hydrophobicity, the helix
orientation toward a membrane interface, the conformational
stability of the structure in membrane, and the presence of a
charged residue, only four peptides met the criteria; one was
synthesized.
Biophysical assays on liposomes clearly showed that the
peptide is fusogenic and destabilizes lipid vesicles with
an efﬁcacy slightly superior to the SIV tilted peptide, the
paradigm in the domain. Peptide 97,848 is mainly helical in
water solution and in lipids, in agreement with its stability
during the angular dynamics.
The systematic test of the peptide insertion in IMPALA
clearly demonstrates that the peptide’s center of mass might
easily ﬂuctuate between 613 A˚ and 65 A˚ close to the
phospholipid headgroups/acyl-chain interface. This suggest
that the peptide has easy access to a wide range of membrane
levels and the existence of such metastable positions was
already suggested for other tilted peptides (28) and should
contribute to their destabilizing capacity.
The stability of the peptide was investigated by 10,000
steps of angular dynamics. The main beneﬁt of angular
FIGURE 6 Angular dynamics course of
peptide 97,848 in IMPALA membrane. The
total number of steps is 10,000. (a) Evolution
of IMPALA restraint energy (kcal/mol). (b)
Evolution of peptide intramolecular energy.
(c) Evolution of the peptide mass center
position. (d) Evolution of the helix axis
insertion angle (). (e) Membrane position
of peptide 97,848 residues in the most stable
conﬁguration of the angular dynamics simu-
lation. The dotted line (interface) indicates
where the water concentration is equal to 0.5.
(f) The stick view of the most stable con-
formation of the angular dynamics simula-
tion. This view is made in conditions similar
to those shown in Fig. 5.
TABLE 3 Leakage of liposome contents (LUV) and core-mixing
assays in the presence of increasing amounts of peptide 97,848
after 15-min incubation
Peptide
concentration
TFE
(blank)
SIV
150 mM 30 mM 60 mM 150 mM 300 mM
% leakage 0 60 38 44 67 83
% core-mixing 0 35 20 26 43 67
100% is established by lysing liposome vesicles with Triton X-100, 0.5%
(EDTA, 10 mM). The SIV peptide is used as a positive control.
TABLE 4 Conformation of peptide 97,848 (85% pure) alone
and in presence of lipids (PC/PE 2:1 w/w) as determined
by attenuated total reﬂection FTIR spectroscopy
a-helix b-sheet b-turn Random coil
Peptide 97,848 alone 52 6 4% 23 6 3% 14 6 2% 11 6 3%
Peptide 97,848 1 lipids 60 6 5% 21 6 4% 9 6 3% 9 6 2%
The values are means 6 SE from three independent experiments.
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versus molecular dynamics lies in its efﬁcacy to investigate
large molecular movement within a reasonable delay (34).
For instance, the angular dynamics procedure required 1/100
the number of calculation steps that the molecular dynamics
needed to explore the same conformational space of rotamer
movements. Investigation of large movement is facilitated
by the use of the Levitt’s modiﬁcation of Lennard Jones
equation for the Van der Waals energy term. Indeed, one
major problem in dynamics studies is due to the fact that all
movements are discrete steps, not soft continuous move-
ment. Hence, if steps are very short, steric clashes can be
avoided, but the equilibrium will be reached after very long
computations. As soon as movements are larger, steric clashes
and thus, Van de Waals energy bursts, create problems in the
computation of energy minimization. This is why Levitt’s
modiﬁcation of the Van der Waals energy, which limits the
energy burst of a steric clash to a value, one that we ﬁxed to
1,000 kcal in this case, is helpful. In other experiments, the
value was set to range between 100 and 10,000 kcal, accord-
ing to the size of the molecule. The goal is to leave room for
a balancing effect of the other energy terms for the entire
course of the dynamics. The angular dynamics is interesting,
because the movement is distributed in the structure, and the
rotation of a f- or c-angle in the middle of the structure will
have more structural consequences than the rotation of an
equivalent axis on the N- or the C-side or than the rotation of
x-angles of side chain. Cooperative stability of folded do-
mains is, by this way, clearly evidenced. In the hydrophobic
domain of IMPALA membrane, the peptide 97,848 back-
bone remains stable; f/c-values are little changed while side
chains are moving, creating intramolecular steric contacts
that disappear after 2,000 steps—supporting the conclusion
that the structure has found a local energy minimum.
Those results suggest that the peptide is stable in the mem-
brane and that its insertion might generate conditions where
lipid perturbation can occur and lead to a fusion process.
From this study, we support the idea that peptides with
speciﬁc lipid-interacting properties can be de novo-designed
using bioinformatic tools. The experimental tests validate
the approach since a de novo peptide was able to destabilize
liposomes and to adopt a stable helical conformation. By
enabling the easy use of modiﬁed residues, the methods
described in this article should be widely interesting even at a
therapeutic design point of view. Indeed, non-natural amino
acids may be more resistant to protease degradation and pres-
ent a more decreased immunogenicity than natural ones (10),
and speciﬁc lipid binding capacities could be useful to target
virosomes and liposomes to speciﬁc cell types.
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